Competitive Clinical Research Grant
Lilly’s grant supports investigator-led clinical research on lebrikizumab in dermatology and mirkizumab in IBD, focusing on efficacy, real-world outcomes, and epidemiology.
Funder: Eli Lilly and Company
Due Dates: February 15, 2026 (Lebrikizumab/fibrosing skin conditions RFP & Atopic dermatitis RFP) | June 15, 2026 (Mirkizumab/IBD Canada RFP)
Funding Amounts: Study drug and/or financial support; typical award size and duration not specified—varies by proposal and RFP.
Summary: Supports investigator-initiated clinical research aligned with Lilly’s public RFPs in areas of dermatology and gastroenterology.
Description
Eli Lilly and Company's Competitive Clinical Research Grant program provides support for external, investigator-initiated clinical studies through public Requests for Proposals (RFPs). Funding may include provision of study drug and/or financial support, depending on the needs of the proposed research and the focus area outlined in each RFP. Proposals are evaluated by global committees of Lilly medical and scientific experts, with possible involvement of external reviewers. Grantees are responsible for the design, conduct, and regulatory sponsorship of the approved research.
Current RFPs focus on:
- The efficacy of lebrikizumab in patients with fibrosing skin conditions
- The impact of lebrikizumab on post-inflammatory dyspigmentation in moderate to severe atopic dermatitis
- The real-world effectiveness of mirkizumab in inflammatory bowel disease (IBD) and epidemiology in overweight and/or obese individuals with IBD in Canada
